Drugs / Orialpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300202 | Feb → Jun 2025 | breast cancer | Oriplantee Company Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Orialpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300202 ↗ |
| Known as | BD-C | “Orialpha (BD-C) at 0.25 x anticipated therapeutic dose” NCT07300202 ↗ |
| Route | Oral | “Dosage form: Powder for oral suspension (sachet)” NCT07300202 ↗ |